Clik here to view.
Transition partner doses first Down syndrome patient
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has announced the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Transition’s licensing partner, Elan Corp., is responsible for all...
View ArticleClik here to view.
Canaccord ups Transition to speculative buy
Canaccord Genuity has upgraded Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) to “speculative buy” from “hold” and raised its price target to $9.80 from $4.75. The stock closed at $5.86 on the TSX on...
View ArticleClik here to view.
Transition, Perrigo amend ELND005 program
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) and Perrigo plc (NYSE,TASE:PRGO) have amended the development and commercialization program for their ELND005 drug candidate, which is being investigated...
View ArticleClik here to view.
Transition in private placement of up to $30.8-million
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has arranged a private placement with Jack Schuler, Larry Feinberg, Oracle Investment Management, certain Transition board members, management and other...
View ArticleClik here to view.
Transition reports positive tQT study for ELND005
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has presented positive results at the Clinical Trials in Alzheimer’s Disease conference from a thorough QT (tQT) study in which no QT effects were...
View Article